The purpose of the trial is to determine whether SIR9900 is safe and works better than the placebo, first by finding the best dose and then by seeing if it improves overall health in people with the disease. In the first part, participants are randomly assigned to receive either a low dose, a higher dose, or the placebo, and safety information such as side effects and lab test results is collected. In the second part, the dose that showed the most promise is given to a new group of participants, again compared with the placebo, to see if it leads to a better overall clinical response, meaning a noticeable improvement in symptoms.

During the study, participants will visit the clinic regularly for check‑ups, blood draws, and simple examinations, and they will be asked to report any new symptoms or problems. The study follows participants for several months, allowing researchers to watch for side effects, track changes in blood tests, and assess how well the medication controls the disease while participants continue any standard treatments they may be using.

The purpose of the study is to determine if starting the GLP-1 therapy enhances the protective effect of the pneumococcal vaccine. Participants are given the vaccine and then either begin treatment with the study medication or continue with usual care (some may receive a placebo). Blood samples are taken a short time after vaccination and again several months later to see how well the immune system has responded, while safety is checked through routine visits and questionnaires.

In simple terms, the researchers measure the level of IgG antibodies, which are proteins that help the body recognize and fight the bacteria. They also look at markers of inflammation (signs that the body is reacting to infection) and count certain immune cells to see if the medication changes their numbers or function. Any side effects or serious health problems related to infection are recorded throughout the study.

After enrollment, participants will receive a series of injections of BMS-986528 over several weeks or months, with regular clinic visits for physical examinations and blood draws. The schedule includes an initial screening, a baseline visit, and follow‑up visits where doctors check for any side effects and collect blood samples to see how the drug moves through the body. The study is open‑label, meaning both the researchers and participants know which treatment is being given.

Safety will be assessed by counting any mild or serious side effects that occur during the study. Blood tests will also look at the amount of the drug present, changes in certain immune cells, levels of proteins called immunoglobulins, and whether the body creates its own antibodies against the drug. In addition, the effect on arthritis symptoms will be measured after about three months using a scoring system called DAS28-CRP, which combines joint swelling, pain, and a blood marker of inflammation to give an overall picture of disease activity.

The purpose of this study is to determine what concentration of Blomia tropicalis extract creates a skin reaction equal in size to the reaction caused by a standard histamine solution. During the study, small amounts of these solutions will be applied to the skin through tiny pricks to measure the body’s allergic response. The skin’s reaction appears as a raised bump called a wheal.

The study involves a single visit where participants receive several skin prick tests with different concentrations of the allergen extract and control solutions. All solutions are applied to the skin surface only. The study will monitor any side effects that might occur during or after the testing procedure.

The purpose of the study is to see whether this combination can more effectively control the disease while remaining safe. Participants will receive the medication cycles over several months, with regular clinic visits for drug administration, blood tests, and eye examinations to watch for any side effects. The study follows each person from the start of treatment through a follow‑up period to observe how the disease responds.

Effectiveness will be judged mainly by the proportion of people who achieve a Complete Hematologic Response, meaning blood tests show no detectable disease activity. Additional assessments include improvement in the function of affected organs (heart, kidney, liver) and monitoring of eye health because the antibody can cause changes on the surface of the eye. Safety will be tracked by recording any unwanted events, changes in laboratory results, and any signs of the body forming antibodies against the new drug.

The purpose of the study is to evaluate the safety, tolerability, and how the body handles the drug (pharmacokinetics) as well as its effect on reducing protein loss in urine. Researchers will monitor side effects, vital signs, and laboratory tests, and will also measure changes in the urine protein-to-creatinine ratio (UPCR) and kidney function using the estimated glomerular filtration rate (eGFR).

Participants will receive the study medication by injection at regular intervals over several months, with clinic visits for assessments and urine or blood collection to check protein levels, antibody levels such as anti-PLA2R antibody, and the number of immune cells called B-cell. The study continues for up to two years, allowing researchers to see both short‑term and longer‑term effects of the treatment.

The purpose of the study is to evaluate the effectiveness and safety of different doses of the medication in adults with moderate to severe disease. Participants are randomly assigned to receive either the medication or the placebo by injection under the skin at regular visits for about 16 weeks. Throughout the trial, researchers check the condition of the skin, the amount of pain, quality of life and any side effects, while the study is conducted in a double‑blind manner so that neither the participants nor the study staff know which treatment is being given.

The purpose of the study is to determine the safety and tolerability of these regimens in people with this condition. Participants are randomly assigned to receive either the active medication or the placebo, and neither the participants nor the study staff know which treatment is given. Over a period of several weeks, participants attend regular visits where vital signs, laboratory tests, and symptom questionnaires such as the MG-ADL (a simple survey that asks about daily activities affected by muscle weakness) are collected to monitor any side effects and changes in disease symptoms.

Participants in the study will receive either the MK-6194 treatment or a placebo. The study will last for about a year, during which participants will have regular check-ups to monitor their progress. The main focus will be on changes in the skin condition, particularly on the face, over a 24-week period. The study will also keep track of any side effects experienced by participants.

By the end of the study, researchers hope to gather enough information to understand how well MK-6194 works in improving the skin condition and how safe it is for patients. This information could help in developing new treatments for people with non-segmental vitiligo in the future.

The purpose of the study is to assess how effective LY3454738 is in treating adults with moderate-to-severe atopic dermatitis. The study will last for 52 weeks, during which participants will receive regular injections and be monitored for any changes in their condition. The study aims to see if LY3454738 can help reduce the symptoms of atopic dermatitis, such as the extent and severity of the eczema.

Participants will be randomly assigned to receive either the active treatment or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will help determine if LY3454738 is a safe and effective option for people with moderate-to-severe atopic dermatitis who have not had significant improvement with topical treatments.